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Abstract: The aim of this study was to compare the effects of mild energy restriction and resveratrol
on thermogenic and oxidative capacity in interscapular brown adipose tissue (IBAT) and in skeletal
muscle. Rats were fed a high-fat high-sucrose diet for six weeks, and divided into four experimental
groups fed a standard diet: a control group, a resveratrol-treated group, an energy-restricted
group and an energy-restricted group treated with resveratrol. Weights of IBAT, gastrocnemius
muscle and fat depots were measured. Activities of carnitine palmitoyltransferase (CPT) and
citrate synthase (CS), protein levels of sirtuin (SIRT1 and 3), uncoupling proteins (UCP1 and 3),
glucose transporter (GLUT4), mitochondrial transcription factor (TFAM), nuclear respiratory factor
(NRF1), peroxisome proliferator-activated receptor (PPARα) and AMP activated protein kinase
(AMPK) and peroxisome proliferator-activated receptor gamma coactivator (PGC1α) activation were
measured. No changes in IBAT and gastrocnemius weights were found. Energy-restriction, but not
resveratrol, decreased the weights of adipose depots. In IBAT, resveratrol enhanced thermogenesis
activating the SIRT1/PGC1α/PPARα axis. Resveratrol also induced fatty acid oxidation and glucose
uptake. These effects were similar when resveratrol was combined with energy restriction. In the case
of gastrocnemius muscle, the effects were not as clear as in the case of IBAT. In this tissue, resveratrol
increased oxidative capacity. The combination of resveratrol and energy restriction seemingly did not
improve the effects induced by the polyphenol alone.
Keywords: resveratrol; energy restriction; thermogenesis; high-fat high-sucrose diet; rat
1. Introduction
The phenomenon of adaptive thermogenesis, also known as non-shivering or facultative
thermogenesis, is a phenomenon characterized by heat production in response to environmental
temperature or diet [1]. It is mediated by the action of uncoupling proteins (UCPs), a type of protein
embedded in the inner mitochondrial membrane which uncouples the oxidative phosphorylation.
As a result, the proton gradient is dissipated and used to produce heat instead of synthetizing adenosine
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triphosphate (ATP) [2]. In this regard, brown adipose tissue (BAT) has been identified as the main
thermogenic tissue, due to its high content in mitochondria [3,4]. This tissue was thought to exist only
in small mammals and newborns, but the recent discovery of BAT in adult humans has reactivated the
interest of the scientific community in this tissue as a possible means of body weight management [5–7].
To produce heat, the lipids stored in BAT are firstly used as substrates [8] and then, in order to
maintain this thermogenic activity, triglycerides from circulation are used [9]. Moreover, circulating glucose
is also used by BAT as a substrate for thermogenesis [9]. As a result, both plasma triglyceride levels
as well as plasma glucose levels are decreased by BAT thermogenic activity [9]. All these observations
highlighted BAT as an interesting target-tissue for obesity and metabolic syndrome management.
Along with BAT, the other main thermogenic tissue in human body is skeletal muscle, which is
the largest organ of the human body and determines the basal metabolic rate [10,11]. UCP3 is the
characteristic uncoupling protein present in this tissue [12]. Although UCP3 was at first thought
to participate in thermogenesis and energy expenditure (as does its more abundant ortholog UCP1,
present in BAT), it has been proposed that its function is more related to glucose and fatty acid
metabolism [13,14].
As previously mentioned, diet is one of the main modulators of thermogenesis, mediating this
process in two different ways. It has been reported that macronutrient composition of the diet can
influence thermogenic activity in animal models not only in BAT, but also in skeletal muscle [15].
Moreover, a reduction in energy intake has also been related to thermogenesis regulation. In this regard,
while excess food intake (hyperphagia) has been related to increased thermogenesis (diet-induced
thermogenesis), reductions in UCP1 mRNA in BAT have been identified in conditions of food
scarcity [16].
In recent years interest in natural compounds with positive health effects has increased within
scientific community. One of these bioactive compounds, resveratrol (3,5,4′-trihydroxy-trans-stilbene),
a phenolic compound belonging to the stilbene group, has attracted a great deal of attention [17–19].
As reported by several authors, resveratrol is able to mimic the effects induced by dietary energy
restriction without reducing caloric intake [20,21]. In addition, many studies have described resveratrol
as a potential inducer of thermogenesis in rodent models fed obesogenic [22] or standard [23] diets.
In this context, the present study aimed to compare the effects of mild energy restriction and
resveratrol on thermogenic capacity of BAT and skeletal muscle, in terms of efficiency and mechanisms
of action. Moreover, the capacity of resveratrol to induce thermogenesis under energy restriction
feeding conditions was also studied.
2. Material and Methods
2.1. Animals, Diets and Experimental Design
The experiment was conducted using 36 six-week-old male Wistar rats (Harlan Ibérica, Barcelona,
Spain), and conducted in accordance with the University of the Basque Country’s Guide for the Care
and Use of Laboratory Animals (Reference protocol approval M20_2016_039). The rats, individually
housed in polycarbonate metabolic cages (Tecniplast Gazzada, Buguggiate, Italy), were placed in
a controlled air-conditioned room (22 ± 2 ◦C) with a 12-h light-dark cycle. After a 6-day adaptation
period, animals were fed a high-fat high-sucrose (HFHS) diet (OpenSource Diets, Lynge, Denmark;
Ref. D12451) for 6 weeks (45% of energy as fat, 13% of energy as sucrose and 4.7 kcal/g of energy)
(Table S1 A). After this period, the animals were fed over 6 additional weeks with a standard
semi-purified diet (OpenSource Diets, Lynge, Denmark; Ref. D10012G) which provided 3.9 kcal/g,
16% as fat, 64% as carbohydrates and 20% as protein (Table S1 B), and randomly distributed into four
experimental groups (n = 9): the control group (C), the resveratrol group (RSV), the restricted group
(R) and the combined group (RR) (Figure S1). The RSV group was treated with a dose of 30 mg/kg
body weight/day of resveratrol, the R group was submitted to a mild energy restriction of 15% of total
daily energy intake and the combined group was submitted to a mild energy restriction (15%) and
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treated with resveratrol (30 mg/kg body weight/day). In the case of C and RSV groups, the animals
had free access to food and water (ad libitum). The selected resveratrol dose was based on the previous
experience of our group [24]. In order to calculate the exact diet amount provided to the animals in the
restricted groups, the spontaneous food intake of the C group rats was taken into account.
Once the whole experimental period (12 weeks) was completed, animals from the four
experimental groups were sacrificed after an overnight fasting (12 h) under anesthesia (chloral hydrate)
by cardiac exsanguination. Interscapular BAT (IBAT), gastrocnemius muscles and white adipose tissue
depots from different anatomical locations (subcutaneous, mesenteric, perirenal and epididymal) were
dissected, weighed, and immediately frozen in liquid nitrogen. All the samples were stored at −80 ◦C
until analysis.
2.2. Enzyme Activities
The activity of carnitine palmitoyltransferase-1a and b (CPT-1a and CPT-1b) was measured
spectrophotometrically in the mitochondrial fraction of IBAT and gastrocnemius muscle, respectively.
Briefly, tissue samples (200 mg) were homogenized in 3 volumes (wt/vol) of buffer containing
10 mmol/L Tris-HCl, 1 mmol/L EDTA and 0.25 mol/L sucrose (pH 7.4), and then centrifuged
(700× g for 10 min at 4 ◦C). After this first centrifugation, the supernatants were collected and
centrifuged again (12,000× g for 15 min at 4 ◦C). The pellets were resuspended in resuspension buffer
(220 mmol/L mannitol, 70 mmol/L sucrose, 1 mmol/L ethylenediaminetetraacetic acid (EDTA) and
2 mmol/L 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), pH 7.4), and the protein
content determined according to the Bradford method [25]. The activity of CPT-1a and CPT-1b was
measured by using the Bieber et al. method [26,27]. The activity of the enzyme was represented as
nanomoles CoA formed per minute, per milligram of protein.
In the case of citrate synthase (CS), activity was also assessed spectrophotometrically, following
the Srere method [27] by measuring the appearance of free CoA. Briefly, frozen IBAT and gastrocnemius
muscle samples (50 and 100 mg respectively) were homogenized in 25 vol (wt/vol) of 0.1 M Tris-HCl
buffer (pH 8.0). Homogenates were incubated for 2 min at 30 ◦C with 0.1 M Tris-HCl buffer containing
0.1 mM 5,5′-dithio-bis-[2-nitrobenzoic acid] (DTNB), 0.25 Triton X-100, 0.5 mM oxalacetate and 0.31 mM
acetyl CoA, and readings were taken at 412 nm. CS activity was expressed as nmol CoA formed per
minute, per milligram of protein. The protein content of the samples was determined by the Bradford
method [25], using bovine serum albumine as standard.
2.3. Western Blot
For sirtuin 1 and 3 (SIRT1 and SIRT3), AMP activated protein kinase (AMPK), glucose transporter
4 (GLUT4), mitochondrial transcription factor A (TFAM), uncoupling proteins 1 and 3 (UCP1 and
UCP3) and Tubulin, IBAT and gastrocnemius muscle samples (100 mg) were homogenized in
1000 µL of cellular phosphate buffer saline (PBS) (pH 7.4), containing protease inhibitors (100 mM
phenylmethylsulfonyl fluoride and 100 mM iodoacetamide). Homogenates were centrifuged at
800× g for 10 min at 4 ◦C. Protein concentration in homogenates was measured by Bradford
method (Bradford et al., 1976) using bovine serum albumin as standard. In the case of peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), nuclear respiratory factor 1 (NRF1),
peroxisome proliferator-activated receptor alpha and beta/delta (PPARα and PPARβ/δ) and histone
H3 (Histone H3), nuclear protein extraction were carried out with 100 mg of IBAT and gastrocnemius
muscle, as previously described [28].
Immunoblot analyses were carried out using 50 µg and 40 µg of IBAT and gastrocnemius muscle
total protein extracts (respectively), and 35 µg and 60 µg of IBAT and gastrocnemius muscle nuclear
protein extracts (respectively), separated by electrophoresis in precast 4–15% sodium dodecyl sulfate
(SDS)-polyacrylamide gradient gels (Bio-Rad, Hercules, CA, USA) and transferred to PVDF membranes
(Bio-Rad, Hercules, CA, USA). The membranes were then blocked with 5% caseine PBS-Tween buffer
for 2 h at room temperature. Subsequently, they were blotted with the appropriate antibodies overnight
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at 4 ◦C. Protein levels were detected via specific antibodies (Table S2) for SIRT3 (1:500), UCP1 (1:500),
UCP3 (1:500), TFAM (1:500), GLUT4 (1:5000), PPARβ/δ (1:500) (Santa Cruz Biotech, Dallas, TX,
USA), AMPK (1:1000), Tubulin (1:5000), Histone H3 (1:1000) (Cell Signaling Technology, Danvers,
MA, USA) and SIRT1 (1:1000), PGC1α (1:1000), NRF1 (1:1000), PPARα (1:1000) (Abcam, Cambridge,
UK). Afterward, polyclonal anti-mouse for SIRT3 (1:5000) (Santa Cruz Biotech, Dallas, TX, USA),
anti-goat for UCP1, UCP3, TFAM and GLUT4 (1:5000) (Santa Cruz Biotech, Dallas, TX, USA) and
anti-rabbit for SIRT1, AMPK, Tubulin, Histone H3, PGC1α, NRF1, PPARα and PPAR β/δ (1:5000)
(Santa Cruz Biotech, Dallas, TX, USA) were incubated for 2 h at room temperature, and the levels of
the aforementioned proteins were measured (Table S2). After antibody stripping, the membranes were
blocked and then incubated with phosphorylated AMPK (threonine 172, 1:1000), and acetylated lysine
(1:1000) (Cell Signaling Technology, Danvers, MA, USA) antibodies (Table S2). The bound antibodies
were visualized by an electrochemiluminescence (ECL) system (Thermo Fisher Scientific Inc., Rockford,
IL, USA) and quantified by a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). Specific
bands were identified by using a standard loading buffer (Precision Plus protein standards dual color;
Ref. 161-0374 Bio-Rad).
2.4. Statistical Analysis
Results are presented as mean ± standard error of the mean (SEM). Statistical analysis was
performed using SPSS 21.0 (SPSS, Chicago, IL, USA). All the variables were normally-distributed
according to the Shapiro-Wilks test. Data were analyzed by one-way analysis of variance (ANOVA)
followed by the Newman–Keuls post hoc test. Significance was assessed at the p < 0.05 level.
3. Results
3.1. Body Weight, Food Intake, Adipose Tissue Weights, and Interscapular Brown Adipose Tissue (IBAT) and
Skeletal Muscle Weights
At the end of the whole experimental period, as expected, significantly lower body weights were
observed in the groups submitted to energy restriction (R and RR) compared with the C group with
no differences among them. In the case of the RSV group, body weight was similar to that found
in the C group [29]. In the same line, significantly lower food intakes were found in both restricted
groups (R and RR) compared with the C group, without differences between them [30]. When the
weights of the four white adipose depots were pooled, a similar pattern to that found in the body
weights, lower values in the restricted groups (R and RR) and no changes in the group treated with
resveratrol (RSV) were noted (Table 1). Finally, IBAT and gastrocnemious weights did not show
significant differences among the four experimental groups (Table 1).
Table 1. Weights of IBAT, gastrocnemius muscle and subcutaneous, perirenal, mesenteric and
epididymal adipose tissues of rats fed on the experimental diets for 6 weeks.
C RSV R RR ANOVA
IBAT (g) 0.76 ± 0.07 0.83 ± 0.03 0.83 ± 0.03 0.82 ± 0.06 NS
Gastrocnemius (g) 2.42 ± 0.03 2.65 ± 0.16 2.62 ± 0.10 2.60 ± 0.08 NS
Subcutaneous AT (g) 14.6 ± 1.1ab 15.2 ± 0.9a 12.0 ± 0.6bc 10.4 ± 0.6c (p < 0.01)
Perirenal AT (g) 14.6 ± 1.4a 13.6 ± 0.8a 8.7 ± 0.3b 9.3 ± 0.5b (p < 0.05)
Mesenteric AT (g) 3.9 ± 0.4ab 4.3 ± 0.1a 2.9 ± 0.3bc 268 ± 0.2c (p < 0.05)
Epididymal AT (g) 11.0 ± 0.9a 12.4 ± 0.2a 7.4 ± 0.5b 7.1 ± 0.5b (p < 0.01)
IBAT, interscapular brown adipose tissue; AT, adipose tissue. Values are mean ± standard error of the mean (SEM).
Differences among groups were determined by using one-way analysis of variance (ANOVA) followed by Newman
Keuls post-hoc test. Values not sharing a common letter are significantly different. NS: Not significant.
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3.2. Enzyme Activities
Regarding CPT-1a in IBAT, significantly greater enzyme activities were observed in the three
treated groups when compared with the C group (p = 0.001 in RSV, p = 0.004 in R and p = 0.020 in RR),
with no differences among them (Figure 1A). As far as gastrocnemius muscle is concerned, a statistically
significant increase in the activity of CPT-1b enzyme was observed in the groups supplemented with
resveratrol (RSV and RR) when compared with the C group (p = 0.017 and p = 0.023, respectively),
while in the case of the R group a non significant trend towards a greater activity (+19.1%; p = 0.065)
was observed (Figure 2A).
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Figure 1. Activities of CPT-1a (A) and CS (B) in IBAT of rats fed an obesogenic diet for 6 weeks and
then shifted to a standard diet (C), or standard diet supplemented with resveratrol (RSV), or submitted
to energy restriction and fed a standard diet (R), or submitted to energy restriction and fed a standard
diet supplemented with resveratrol (RR) (n = 9/group) for additional 6 weeks. Values are represented
as means ± SEM. Differences among groups were determined by using one-way ANOVA followed
by Newman–Keuls post hoc test. Values not sharing a common letter are significantly different
(p < 0.05). CPT-1a: carnitine palmitoyltransferase-1a, CS: citrate synthase, IBAT: interscapular brown
adipose tissue.
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Figure 2. Activities of CPT-1b (A) and CS (B) in gastrocnemius muscle of rats fed an obesogenic diet
for 6 weeks and then shifted to a standard diet (C), or standard diet supplemented with resveratrol
(RSV), or submitted to energy restriction and fed a standard diet (R), or submitted to energy restriction
and fed a standard diet supplemented with resveratrol (RR) (n = 9/group) for additional 6 weeks.
Values are represented as means± SEM. Differences among groups were determined by using one-way
ANOVA followed by Newman–Keuls post hoc test. Values not sharing a common letter are significantly
different (p < 0.05). CPT-1b: carnitine palmitoyltransferase-1b, CS: citrate synthase.
In the case of the CS, RSV and RR groups, these showed a significantly increased enzyme activity
in IBAT when compared with the C group (p = 0.05 and p = 0.04, respectively) (Figure 1B). A trend
towards greater enzyme activities was appreciated in R group when compared with the C group
(+47.9%; p = 0.078) (Figure 1B). In gastrocnemius muscle, no changes in the activity of this enzyme
were found among the four experimental groups (Figure 2B).
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3.3. Western Blot Analysis in IBAT and Skeletal Muscle
In order to analyze the effects induced by resveratrol administration, energy restriction and
the combination on IBAT and skeletal muscle thermogenic capacities and fatty acid oxidation,
the expression or the activation of different proteins was analyzed (Figure 3).
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In IBAT, increased UCP1 protein expression was found in the group supplemented with resveratrol
(RSV) in comparison with the C group (p = 0.03), as well as a tendency towards higher values in the
RR group (+49.9%; p = 0.10) and no changes in the R group (Figure 4). In order to determine the
molecular mechanisms underlying this effect, PGC1α, PPARα and SIRTs were studied. Decreased
PGC1α acetylation, and thus greater activation of this protein, was found in the RSV and RR groups
when compared with the C group (p = 0.02 and p = 0.03, respectively). In the case of R group,
a tendency towards lower acetylation (−29.5%; p = 0.06) was observed (Figure 5). Regarding PPARα,
although no differences in protein expression were found in the C group and the three treated groups,
trends towards increased expressions were appreciated (+43.6%; p = 0.055 in the RSV group, +59.3%;
p = 0.073 in the R group and +51.8%; p = 0.053 in the RR group) (Figure 5). Similarly, no significant
changes were observed among the four groups in SIRT1 protein expression, but trends towards
increased protein levels were found in the three treated groups when compared with the C group
(+37.6%; p = 0.057 in the RSV group, +49.6%; p = 0.094 in the R group and +45.7%; p = 0.065 in the
RR group) (Figure 4). As far as SIRT3 is concerned, greater protein levels ere found in the three
treated groups hen co pared ith the C group (p = 0.05 in RSV, p = 0.033 in R and p = 0.019 in RR),
ith no differences among them (Figure 4). Finally, the phosphorylation ratio of threonine 172 residue
was measured in AMPK to analyze its activation status. The groups supplemented with resveratrol
(RSV and RR) showed greater phosphorylation ratios in comparison with the C group (p = 0.022 and
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p = 0.045, respectively), without differences between them. In the case of the R group, no significant
change in the phosphorylation ratio (and thus, in the activity) was found (Figure 4).Nutrients 2018, 10, x FOR PEER REVIEW  7 of 16 
 
 
Figure 4. Protein levels of SIRT1, GLUT4, UCP1, SIRT3 and TFAM, and threonine 172 
phosphorylation ratio of AMPK in IBAT of rats fed an obesogenic diet for 6 weeks and then shifted 
to a standard diet (C), or standard diet supplemented with resveratrol (RSV), or submitted to energy 
restriction and fed a standard diet (R), or submitted to energy restriction and fed a standard diet 
supplemented with resveratrol (RR) (n = 9/group) for additional 6 weeks. Values are represented as 
means ± SEM. Differences among groups were determined by using one-way ANOVA followed by 
Newman–Keuls post hoc test. Values not sharing a common letter are significantly different (p < 0.05). 
SIRT1: sirtuin 1, GLUT4: glucose transporter 4, UCP1: uncoupling protein 1, SIRT3: sirtuin 3, TFAM: 
mitochondrial transcription factor A, AMPK: AMP activated protein kinase, IBAT: interscapular 
brown adipose tissue. 
Figure 4. Protein levels of SIRT1, GLUT4, UCP1, SIRT3 and TFAM, and threonine 172 phosphorylation
ratio of AMPK in IBAT of rats fed an obesogenic diet for 6 weeks and then shifted to a standard
diet (C), or standard diet supplemented with resveratrol (RSV), or submitted to energy restriction
and fed a standard diet (R), or submitted to energy restriction and fed a standard diet supplemented
with resveratrol (RR) (n = 9/group) for additional 6 weeks. Values are represented as means ± SEM.
Differences among groups were determined by using one-way ANOVA followed by Newman–Keuls
post hoc test. Values not sharing a common letter are significantly different (p < 0.05). SIRT1: sirtuin 1,
GLUT4: glucose transporter 4, UCP1: uncoupling protein 1, SIRT3: sirtuin 3, TFAM: mitochondrial
transcription factor A, AMPK: AMP activated protein kinase, IBAT: interscapular brown adipose tissue.
Mitochondriogenesis is a process closely related to thermogenesis. Thus, proteins involved in
this process were also analyzed. Increased protein expressions of NRF1 were found in the RSV, R and
RR groups when compared with the C group (p = 0.04, p = 0.01 and p = 0.02, respectively), with no
differences among them (Figure 5). A similar pattern of response was observed in TFAM protein
levels (p = 0.04 in the RSV group, p = 0.02 in the R group and p = 0.04 in the RR group) (Figure 4).
In addition, GLUT4 protein level, a glucose transporter that provides with this energy substrate to
IBAT, was increased only in the groups supplemented with resveratrol (RSV and RR) (p = 0.048 and
p = 0.050, respectively) (Figure 4).
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remained unchanged (Figures 6 and 7). Similarly, lack of change was also found in NRF1, although 
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the RR group) (Figure 7). By contrast, greater protein expression of TFAM was observed in the three 
Figure 5. Acetylation ratio of PGC1α and protein levels of NRF1 and PPARα in IBAT of rats fed an
obesogenic diet for 6 weeks and then shifted to a standard diet (C), or standard diet supplemented with
resveratrol (RSV), or submitted to energy restriction and fed a standard diet (R), or submitted to energy
restriction and fed a standard diet supplemented with resveratrol (RR) (n = 9/group) for additional
6 weeks. Values are represented as means ± SEM. Differences among groups were determined by
using one-way ANOVA followed by Newman–Keuls post hoc test. Values not sharing a common
letter are significantly different (p < 0.05). PGC1α: peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, NRF1: nuclear respiratory factor 1, PPARα: peroxisome proliferator-activated
receptor alpha, IBAT: interscapular brown adipose tissue.
In the case of gastrocnemius muscle, no effects of the treatments were found in UCP3 protein
expression (Figure 6). Regarding PGC1α, significantly lower acetylation, and thus greater activation of
the protein, was observed in the RSV group in comparison to the C group (p = 0.03). In the case of
restricted groups, only trends towards lower acetylation status were appreciated (−34.7%; p = 0.053 in
R and −30.4%; p = 0.10 in RR) (Figure 7). Protein expressions of PPARβ/δ, SIRT1 and SIRT3 remained
unchanged (Figures 6 and 7). Similarly, lack of change was also found in NRF1, although a trend
towards increased protein expressions was appreciated in the groups submitted to energy restriction
when compared to the C group (+34.7%; p = 0.065 in the R group and +25.5%; p = 0.081 in the RR group)
(Figure 7). By contrast, greater protein expression of TFAM was observed in the three treated groups
in comparison with the C group (p = 0.04 in RSV group, p = 0.02 in the R group and p = 0.04 in the RR
group) (Figure 6). Finally, significantly greater activation of AMPK was only observed in the RR group
when compared with the C group (p = 0.024). In the case of the RSV and R groups, tendencies towards
an increased activation were found (+50.9%; p = 0.082 and +58.9%; p = 0.054, respectively) (Figure 6).
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of P in gastrocne ius uscle of rats fed an obesogenic diet for 6 weeks and then shifted to
a standard diet (C), or standard diet supple ented ith resveratrol (RSV), or sub itted to energy
restriction and fed a standard diet (R), or sub itted to energy restriction and fed a standard diet
supplemented with resveratrol (RR) (n = 9/group) for additional 6 weeks. Values are represented as
means ± SEM. Differences among groups were determined by using one-way ANOVA followed by
Newman–Keuls post hoc test. Values not sharing a common letter are significantly different (p < 0.05).
SIRT1: sirtuin 1, UCP3: uncoupling protein 3, SIRT3: sirtuin 3, TFAM: mitochondrial transcription
factor 1, AMPK: AMP activated protein kinase.
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muscle of rats fed an obesogenic diet for 6 weeks and then shifted to a standard diet (C), or standard
diet supplemented with resveratrol (RSV), or submitted to energy restriction and fed a standard
diet (R), or submitted to energy restriction and fed a standard diet supplemented with resveratrol
(RR) (n = 9/group) for additional 6 weeks. Values are represented as means ± SEM. Differences
among groups were determined by using one-way ANOVA followed by Newman–Keuls post hoc
test. Values not sharing a common letter are significantly different (p < 0.05). PGC1α: peroxisome
proliferator-activated receptor gamma coactivator 1-alpha, NRF1: nuclear respiratory factor 1,
PPAR β/δ: peroxisome proliferator-activated receptor beta/delta.
4. Discussion
As indicated in the introduction, the interest of the scientific community in natural
bioactive compounds with beneficial health effects has been increasing in recent years. Regarding
resveratrol, positive effects on several prevalent diseases have been reported both in animals and
humans [19,31–34]. It is important to emphasize that, with regard to its effects on obesity and related
co-morbilities such as insulin resistance and liver steatosis, the vast majority of the reported studies
addressed in animal models have been carried out by using experimental designs in which resveratrol
was administered together with an obesogenic diet. Consequently, the beneficial effects observed
in these studies were related to the prevention of weight gain and metabolic alterations induced by
this dietary pattern. However, the applicability of such experimental design in humans is unlikely.
Indeed, for ethical reasons, it is not possible to recommend people to take resveratrol while they
maintain an inappropriate dietary pattern.
Bearing this in mind, we focused our interest on the potential beneficial effects of resveratrol
as a tool for obesity treatment. Thus, we assessed its effects on rats that had previously developed
overweight/obesity (induced by diet). For this purpose, two approaches were designed. In the first,
Nutrients 2018, 10, 1446 11 of 16
once obesity induction had stopped resveratrol was administered, as the single tool to treat obesity,
together with a standard diet, while in the other resveratrol was combined with an energetically
restricted diet, which is the most commonly strategy used in obesity treatment
It is important to point out that, in the vast majority of the reported studies, energy restriction
ranges from 20% to 40%. In the present study a lower degree of restriction (15%) was chosen.
The reason was based on a previous study from our group [35]. In that study we looked for synergistic
effects between resveratrol, at a dose of 30 mg/kg of body weight/day, and 25% energy restriction.
We observed that the addition of resveratrol to the restricted diet did not lead to additional reductions
in fat mass or in serum insulin concentrations with regard to those produced by energy restriction
alone. We believed that one of the reasons that could explain this situation was that the effects caused
by energy restriction were strong enough to mask the potential positive effects ascribed to resveratrol.
Consequently, a lower degree of energy restriction was preferred in the present study.
In IBAT, resveratrol administration increased UCP1 protein expression, suggesting a greater
thermogenic capacity. In order to analyze the mechanism underlying this effect, we studied the
regulation pathway described in Figure 3. Resveratrol induced deacetylation, and thus activation,
of PGC1α, a co-activator of PPARα, which in turn regulates the expression of UCP1. It has been
reported that SIRT1 is the main enzyme responsible for PGC1α deacetylation [36]. In the present study,
a tendency towards increased protein expression of SIRT1 was observed. Although its activation was
not directly measured, the deacetylation of PGC1α suggests that it was in fact activated. In addition,
resveratrol increased the activity of AMPK, an enzyme that phosphorylates PGC1α, thus enhancing
its activity. Furthermore, SIRT3 is activated by PGC1α, mediating the effects of this sirtuin on
mitochondrial function and synthesis [37,38]. Moreover, the expression of this deacetylase has
been reported to be positively correlated with a variety of mitochondrial proteins, UCP1 among
them [39]. In the case of our study, significantly increased protein expression of SIRT3 was observed
in resveratrol-treated rats. These results show that resveratrol increased the expression of UCP1 by
activating the SIRT1/PGC1α/PPARα axis.
Fatty acid oxidation is an important part of the thermogenic program. It has been reported
that the activation of PPARα by PGC1α leads to increased NRF1 and the subsequent increase in the
synthesis of TFAM, which in turn results in enhanced duplication of mitochondrial DNA (Figure 3).
Accordingly, in the present study PGC-1α activation was indeed accompanied by increases in NRF1 and
TFAM expressions, suggesting that resveratrol, under the present experimental conditions, enhanced
mitochondriogenesis. This is in good accordance with the increased activities of CPT1a and CS
observed in rats treated with resveratrol. BAT can also use glucose as an energetic substrate. In the
present study resveratrol induced a significant increase in GLUT4 protein expression, meaning that the
capacity of IBAT to uptake glucose was greater in rats treated with this phenolic compound. Taken as
a whole, these results show that resveratrol did not only increase the key factor for thermogenesis
(UCP1) but also the availability of substrates to keep this process activated.
In previous studies from our laboratory we had already observed the induction of UCP1
by resveratrol in IBAT [22,40] and other authors had also reported similar results [41,42]. In all
these studies the animals received the phenolic compound at the same time as an obesogenic diet,
during the fattening period. By contrast, in this work the animals were fed a high-fat high sucrose
diet to become obese and then they were shifted to a standard diet, and treated with resveratrol.
Taken together, the present results and those reported previously demonstrate the ability of resveratrol
to induce thermogenesis under both overfeeding and normal feeding conditions. This may represent
a mechanism of action underlying the beneficial effect of resveratrol in obesity management.
As previously mentioned, a second approach in this study was to analyze the effects induced by
resveratrol under energy restriction. In fact, the usefulness of this phenolic compound in combination
with the most common strategy for obesity treatment was intended to analyze whether potential
additive or synergistic effects could take place. This is an interesting approach because it would
Nutrients 2018, 10, 1446 12 of 16
result in the same positive effect obtained by following a more restricted diet non supplemented with
resveratrol, whose compliance is more difficult to achieve.
For this purpose, first of all we analyzed the effects of energy restriction on the parameters
previously studied in the first approach. No change in UCP1 protein expression was observed in
R group. By contrast, NRF1 and TFAM protein expressions, as well as the CPT1a activity were
significantly increased in these animals, suggesting that mitochondrial synthesis and function were
enhanced. The increased SIRT3 protein expression observed in this experimental group supports the
idea of an ameliorated mitochondrial function, in good accordance with previous data describing the
activation of this protein in different tissues under energy restriction conditions [43–45]. It is important
to remember that resveratrol has been suggested as an energy restriction mimetic [20,21,46,47].
However, as shown by the present results, differential effects on thermogenic capacity are found
between them.
When we analyzed the RR group, in general terms, the effects on the parameters studied were
similar to those observed in the RSV group, although in this case only a trend towards higher values
was observed in UCP1. These results demonstrate that the administration of resveratrol in combination
with energy restriction does not provide any advantage.
In the case of skeletal muscle, the effects of resveratrol were not as clear as in IBAT.
The administration of this polyphenol was not able to increase protein expression of UCP3, despite the
activation of PGC-1α. Nevertheless, increased TFAM protein expression and CPT-1b activity suggest
increased fatty acid oxidation, associated to enhanced mitochondrial synthesis. It has been reported
that the activation of PGC-1α is based on sirtuin-mediated deacetylation and phosphorylation by
AMPK [48,49]. In the case of skeletal muscle, the absence of any significant activation of AMPK by
resveratrol may explain the lack of activation of every single step in mitochondriogenesis pathway,
and consequently in CS activity.
In the studies reported by other authors there is no consensus regarding the effects of resveratrol
on skeletal muscle mitochondrial biogenesis induction. Indeed, while an enhanced mitochondrial
synthesis and/or function has been described in studies where the compound was administered in
conditions of certain metabolic stress [41,50,51], this effect seems to disappear when the polyphenol is
administered in healthy subjects [52–54]. Regarding UCP3, the lack of change found in this study is
not in good accordance with data reported by other authors. In those studies, resveratrol effectively
induced UCP3 mRNA or protein expression in the skeletal muscle of mice and rats fed in obesogenic
diets [22,41]. Moreover, greater UCP3 protein expression was also described in this tissue in mice fed
in a standard diet and supplemented with the polyphenol [55]. Nevertheless, the discrepancy between
our results and those previously reported could result from significant differences in the experimental
design (animal model, experimental period length, resveratrol dose and diet composition).
As far as energy restriction is concerned, no relevant significant changes were observed in the
parameters analysed. By revising data reported in the literature concerning this issue we observed
that some controversy exists. Thus, while some authors have reported that the maintenance of
a 30% energy restriction for a period of 3 months effectively induces mitochondrial biogenesis and
function (increased respiration and expression of genes important for oxidative function), others have
found no such effects under similar experimental conditions [56,57]. In fact, in a study conducted in
mice of different ages (6, 12 and 24 month old B6D2F1 mice) that underwent a lifelong energy restriction
(40%), the authors concluded that energy restriction did not induce mitochondrial protein synthesis,
but maintained this parameter while decreasing cellular proliferation [58]. Moreover, the authors point
towards the techniques used by Nisoli et al., and Hancock et al. in determining the effects of energy
restriction on mitochondrial synthesis (mRNA and protein expression of mitochondrial proteins) as
being the cause of their contradictory results. Finally, when resveratrol was administered under energy
restriction feeding conditions, the results were very similar to those observed when the compound
was administered under standard feeding conditions.
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We would like to point out that in previous studies conducted in this precise cohort of rats aimed
at studying the effects of the aforementioned treatments on glucose homeostasis and hepatic steatosis
([29,30], respectively), resveratrol-induced effects were less marked than those produced by energy
restriction. By contrast, when considering the effects on UCP expression and fatty acid oxidative
capacity, as in the present study, resveratrol was more effective than a mild energy restriction.
In conclusion, in obese rats under standard feeding conditions, resveratrol is able to increase
thermogenic and oxidative capacities in IBAT. This feature represents a mechanism by which this
phenolic compound could show an anti-obesity action. Nevertheless, more research is needed in order
to interpret the importance of this mechanism. In the case of skeletal muscle, oxidative capacity is
increased by this polyphenol intake. The administration of resveratrol in combination with energy
restriction apparently does not provide any advantage.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/10/1446/
s1, Figure S1: Timeline of the complete experimental period (12 weeks), Table S1: Composition of the experimental
(A) High-fat High-sucrose and (B) Standard control diets, Table S2: References of the antibodies used for western
blot analyses.
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